190 related articles for article (PubMed ID: 25724225)
21. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET.
Miller FH; Keppke AL; Reddy D; Huang J; Jin J; Mulcahy MF; Salem R
AJR Am J Roentgenol; 2007 Mar; 188(3):776-83. PubMed ID: 17312068
[TBL] [Abstract][Full Text] [Related]
22. Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques.
Denecke T; Rühl R; Hildebrandt B; Stelter L; Grieser C; Stiepani H; Werk M; Podrabsky P; Plotkin M; Amthauer H; Ricke J; Lopez Hänninen E
Eur Radiol; 2008 May; 18(5):892-902. PubMed ID: 18175122
[TBL] [Abstract][Full Text] [Related]
23. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
25. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
Klingenstein A; Haug AR; Zech CJ; Schaller UC
Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
[TBL] [Abstract][Full Text] [Related]
26. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
27. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy.
Wong CY; Gates VL; Tang B; Campbell J; Qing F; Lewandowski RJ; Thie J; Ho CL; Savin M; Salem R
Cancer Biother Radiopharm; 2010 Apr; 25(2):233-6. PubMed ID: 20423237
[TBL] [Abstract][Full Text] [Related]
28. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
29. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
[TBL] [Abstract][Full Text] [Related]
30. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
[TBL] [Abstract][Full Text] [Related]
31. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Cone-Beam Tomography and Cross-Sectional Imaging for Volumetric and Dosimetric Calculations in Resin Yttrium-90 Radioembolization.
Ertreo M; Choi H; Field D; Lischalk JW; Cohen E; Lynskey GE; Caridi T; Buckley D; Unger K; Kim AY
Cardiovasc Intervent Radiol; 2018 Dec; 41(12):1857-1866. PubMed ID: 30006891
[TBL] [Abstract][Full Text] [Related]
33. Embolization of hepatic arterial branches to simplify hepatic blood flow before yttrium 90 radioembolization: a useful technique in the presence of challenging anatomy.
Karunanithy N; Gordon F; Hodolic M; Al-Nahhas A; Wasan HS; Habib N; Tait NP
Cardiovasc Intervent Radiol; 2011 Apr; 34(2):287-94. PubMed ID: 20700593
[TBL] [Abstract][Full Text] [Related]
34. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.
Reiner CS; Morsbach F; Sah BR; Puippe G; Schaefer N; Pfammatter T; Alkadhi H
J Vasc Interv Radiol; 2014 May; 25(5):747-59. PubMed ID: 24630751
[TBL] [Abstract][Full Text] [Related]
35. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
[TBL] [Abstract][Full Text] [Related]
36. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin.
Algin E; Ozet A; Gumusay O; Cetin B; Akdemir UO; Benekli M; Coskun U; Uner A; Kapucu O; Buyukberber S
Ann Nucl Med; 2014 Nov; 28(9):891-6. PubMed ID: 25270711
[TBL] [Abstract][Full Text] [Related]
37. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
Wong CY; Qing F; Savin M; Campbell J; Gates VL; Sherpa KM; Lewandowski RJ; Nagle C; Salem R
J Vasc Interv Radiol; 2005 Aug; 16(8):1101-6. PubMed ID: 16105922
[TBL] [Abstract][Full Text] [Related]
38. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results.
Veit P; Antoch G; Stergar H; Bockisch A; Forsting M; Kuehl H
Eur Radiol; 2006 Jan; 16(1):80-7. PubMed ID: 15868122
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT.
Veit-Haibach P; Treyer V; Strobel K; Soyka JD; Husmann L; Schaefer NG; Tschopp A; Hany TF
Abdom Imaging; 2010 Oct; 35(5):528-36. PubMed ID: 19593563
[TBL] [Abstract][Full Text] [Related]
40. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI
HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
